BioPharmSignal logoBioPharmSignal

Biotech News

NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference

NewAmsterdam Pharma (NAMS)NewAmsterdam PharmaConference / presentation

NAARDEN, the Netherlands and MIAMI, April 08, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”)

Related news

NAMSNewAmsterdam Pharma2026-07-01 12:00 EST

NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026

MISTMilestone Pharmaceuticals Inc.2026-04-07 12:30 EST

Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

LXRXLexicon Pharmaceuticals2026-05-28 12:30 EST

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

CVRXCVRx2026-05-27 20:30 EST

CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

VANIVivani Medical2026-05-28 12:30 EST

Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026

MNKDMannKind2026-05-27 20:00 EST

MannKind to Present at Jefferies Global Healthcare Conference

MLYSMineralys Therapeutics2026-06-08 20:05 EST

Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

BLTEBelite Bio2026-06-02 12:00 EST

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

BLTEBelite Bio2026-07-15 12:00 EST

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

VANIVivani Medical2026-07-14 20:03 EST

Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

View all latest news

NewAmsterdam Pharma

Oral Lipid-Lowering Therapies NewAmsterdam Pharma develops oral therapies for cardiovascular disease. Its lead program targets CETP to produce substantial reductions in LDL cholesterol. Obicetrapib Obicetrapib is an oral CETP inhibitor being developed for patients who need additional LDL reduction despite existing lipid-lowering...

Recent company news

NAMSNewAmsterdam Pharma2026-08-06 20:01 EST

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAMSNewAmsterdam Pharma2026-08-05 11:00 EST

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

NAMSNewAmsterdam Pharma2026-07-29 12:00 EST

NewAmsterdam Pharma to Host Investor Day on August 5, 2026

NAMSNewAmsterdam Pharma2026-07-24 12:00 EST

NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

NAMSNewAmsterdam Pharma2026-07-02 20:01 EST

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
27.67 USD
Market cap
3.71B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States